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PPARα is a ligand-activated transcription factor involved in the regulation of nutrient metabolism and inflammation. Although
much is already known about the function of PPARα in hepatic lipid metabolism, many PPARα-dependent pathways and genes
have yet to be discovered. In order to obtain an overview of PPARα-regulated genes relevant to lipid metabolism, and to probe
for novel candidate PPARα target genes, livers from several animal studies in which PPARα was activated and/or disabled were
analyzed by Aﬀymetrix GeneChips. Numerous novel PPARα-regulated genes relevant to lipid metabolism were identified. Out of
this set of genes, eight genes were singled out for study of PPARα-dependent regulation in mouse liver and in mouse, rat, and
human primary hepatocytes, including thioredoxin interacting protein (Txnip), electron-transferring-flavoprotein β polypeptide
(Etfb), electron-transferring-flavoprotein dehydrogenase (Etfdh), phosphatidylcholine transfer protein (Pctp), endothelial lipase
(EL, Lipg), adipose triglyceride lipase (Pnpla2), hormone-sensitive lipase (HSL, Lipe), and monoglyceride lipase (Mgll). Using an
in silico screening approach, one or more PPAR response elements (PPREs) were identified in each of these genes. Regulation of
Pnpla2, Lipe, and Mgll, which are involved in triglyceride hydrolysis, was studied under conditions of elevated hepatic lipids. In
wild-type mice fed a high fat diet, the decrease in hepatic lipids following treatment with the PPARα agonist Wy14643 was par-
alleled by significant up-regulation of Pnpla2, Lipe, and Mgll, suggesting that induction of triglyceride hydrolysis may contribute
to the anti-steatotic role of PPARα. Our study illustrates the power of transcriptional profiling to uncover novel PPARα-regulated
genes and pathways in liver.
Copyright © 2007 Maryam Rakhshandehroo et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
The peroxisome-proliferator-activated receptors (PPARs)
play a pivotal role in the regulation of nutrient metabolism.
PPARs are ligand-activated transcription factors that belong
to the superfamily of nuclear hormone receptors [1–3]. They
share a common mode of action that involves formation of
heterodimers with the nuclear receptor RXR, followed by
binding to specific DNA-response elements in the promoter
of target genes. The genomic sequence recognized by PPARs,
referred to as PPAR response element or PPRE, consists of a
direct repeat of the consensus hexameric motif AGGTCA in-
terspaced by a single nucleotide. Binding of ligands to PPARs
leads to recruitment of coactivators and causes chromatin re-
modeling, resulting in initiation of DNA transcription and
upregulation of specific PPAR target genes [4, 5]. Ligands
for PPARs include both endogenous compounds, such as
fatty acids and their eicosanoid derivatives, and synthetic ag-
onists. Three diﬀerent PPAR subtypes have been identified:
PPARα, PPARβ/δ, and PPARγ. The latter isotype, which is
most highly expressed in adipose tissue, is known to play
an important role in adipocyte diﬀerentiation and lipid stor-
age [6–8]. It is a target for an important class of antidiabetic
drugs, the insulin-sensitizing thiazolidinediones. Expression
of PPARβ/δ is ubiquitous and has been connected to wound
healing, cholesterol metabolism, and fatty acid oxidation in
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adipose tissue and muscle [9–12]. Finally, PPARα is highly
expressed in liver where it stimulates fatty acid uptake and ac-
tivation, mitochondrial β-oxidation, peroxisomal fatty acid
oxidation, ketogenesis, and fatty acid elongation and desatu-
ration. In addition, it has a major role in glucose metabolism
[13] and the hepatic acute phase response [14, 15]. Impor-
tantly, PPARα is the molecular target for the hypolipidemic
fibrate class of drugs that lower plasma triglycerides and ele-
vate plasma HDL (high-density lipoprotein) levels.
In recent years, microarray technology has emerged as a
powerful technique to study global gene expression. In the-
ory, microarray analysis is a terrific tool to map PPARα-
dependent genes and further characterizes PPARα function.
In practice, microarray yields a huge amount of data, the
analysis and interpretation of which can be very diﬃcult. Nu-
merous studies have examined the eﬀect of synthetic PPARα
agonists on global gene expression using microarrays. While
these studies uncovered many possible PPARα target genes,
the manner in which the data were presented often rendered
interpretation diﬃcult. Part of the complexity is due to the
size of the PPARα-dependent transcriptome in liver, which
easily exceeds one thousand genes.
The aim of the present study was twofold: (1) to gener-
ate a comprehensive overview of PPARα-regulated genes rel-
evant to hepatic lipid metabolism and (2) to identify possible
novel target genes and target pathways of PPARα connected
with lipid metabolism. To that end, we (1) combined mi-
croarray data from several independent animal experiments
involving PPARα-null mice (in these experiments, mice were
either given Wy14643 or fasted for 24 hours), (2) focused on
up-regulation of genes by PPARα in conformity with the gen-
eral paradigm of transcriptional regulation by nuclear hor-
mone receptors, and (3) reduced complexity by progressively
moving from the complete PPARα-dependent transcriptome
towards genes relevant to lipid metabolism, and finally to
the identification of possible PPARα target genes involved in
lipid metabolism.
2. METHODS AND MATERIALS
2.1. Materials
Wy14643 was obtained from ChemSyn Laboratories
(Lenexa, KS). Recombinant human insulin (Actrapid) was
from Novo Nordisk (Copenhagen, Denmark). SYBR Green
was from Eurogentec (Seraing, Belgium). DMEM, fetal calf
serum, calf serum, and penicillin/streptomycin/fungizone
were from Lonza Bioscience (Verviers, Belgium). Otherwise,
chemicals were from Sigma (Zwijndrecht, The Netherlands).
2.2. Animals
Male pure-bred Sv129 and PPARα-null mice on a Sv129
background were used at 3–5 months of age (Jackson Lab-
oratories, Bar Harbor, ME). Animals were fed normal lab-
oratory chow (RMH-B diet, Arie Blok animal feed, Wo-
erden, the Netherlands). Study 1: fed mice were killed at
the end of the dark cycle. Fasting was started at the onset
of the light cycle for 24 hours (n = 5 per group). Stud-
ies 2 and 4: wild-type and PPARα-null mice were fed with
Wy14643 for 5 days by mixing it in their food (0.1%, n = 5
per group). Studies 2 and 4 were carried out independently
and 2 years apart. Study 3: wild-type and PPARα-null mice
fasted for 4 hours received a single dose of Wy14643 (400 μL
of 10 mg/mL Wy14643 dissolved in 0.5% carboxymethylcel-
lulose) and were killed 6 hours later (n = 5 per group).
Study 5: wild-type and PPARα-null mice at 2-3 months
of age were given a high-fat diet (D12451, Research Di-
ets, New Brunswick, NJ) for 20 weeks (composition avail-
able at http://www.researchdiets.com/pdf/Data%20Sheets/
DIO%20Series.pdf). During the last week, half of the mice
were given Wy14643 for 7 days by mixing it in their food
(0.1%, n = 5 per group). Livers were dissected and imme-
diately frozen in liquid nitrogen.
All animal experiments were approved by the animal
experimentation committee of Wageningen University and
were carried out in conformity with the public health service
(PHS) policy on humane care and use of laboratory animals.
2.3. Primary hepatocytes
Rat (Wistar) and mouse (sv129) hepatocytes were isolated by
two-step collagenase perfusion as described previously [16].
Cells were plated on collagen-coated six-well plates. Viability
was determined by Trypan Blue exclusion, and was at least
75%. Hepatocytes were suspended in William’s E medium
(Lonza Bioscience, Verviers, Belgium) supplemented with
10% (v/v) foetal calf serum, 20 m-units/mL insulin, 50 nM
dexamethasone, 100 U/mL penicillin, 100 μg/mL of strep-
tomycin, 0.25 μg/mL fungizone, and 50 μg/mL gentamycin.
The next day, cells were incubated in fresh medium in the
presence or absence of Wy14643 (10 μM) dissolved in DMSO
for 24 hours, followed by RNA isolation.
Human hepatocytes and Hepatocyte Culture Medium
Bulletkit were purchased from Lonza Bioscience (Verviers,
Belgium). Human hepatocytes were isolated from a single
donor. Cells were plated on collagen-coated six-well plates.
Upon arrival of the cells, the medium was discarded and was
replaced by Hepatocyte Culture Medium. The next day, cells
were incubated in fresh medium in the presence or absence of
Wy14643 (50 μM) dissolved in DMSO for 12 hours, followed
by RNA isolation.
2.4. Affymetrix microarray
Total RNA was prepared from mouse livers and primary
hepatocytes using TRIzol reagent (Invitrogen, Breda, The
Netherlands). RNA was either pooled per group or treatment
(studies 1 and 2, primary hepatocytes), or used individually
(studies 3 and 4), and further purified using RNeasy micro
columns (Qiagen, Venlo, the Netherlands). RNA integrity
was checked on an Agilent 2100 bioanalyzer (Agilent Tech-
nologies, Amsterdam, the Netherlands) using 6000 Nano
Chips according to the manufacturer’s instructions. RNA was
judged as suitable for array hybridization only if samples ex-
hibited intact bands corresponding to the 18S and 28S ribo-
somal RNA subunits, and displayed no chromosomal peaks
or RNA degradation products (RNA Integrity Number >8.0).
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Ten micrograms of RNA were used for one cycle cRNA syn-
thesis (Aﬀymetrix, Santa Clara, CA). Hybridization, wash-
ing, and scanning of Aﬀymetrix Genechip MOE430 (studies
1 and 2) or mouse genome 430 2.0 arrays (studies 3 and 4)
was according to standard Aﬀymetrix protocols.
Scans of the Aﬀymetrix arrays were processed using pack-
ages from the Bioconductor project [17]. Expression levels
of probe sets were calculated using GCRMA [18], followed
by identification of diﬀerentially expressed probe sets us-
ing Limma [19]. Comparison was between fasted wild-type
and fasted PPARα-null mice (study 1) or between Wy14643-
treated wild-type and Wy14643-treated PPARα-null mice
(studies 2–4). P-values were corrected for multiple testing
using a false discovery rate method [20]. Probe sets that sat-
isfied the criterion of FDR <1% (q-value <0.01) and fold-
change >1.5 were considered to be significantly regulated.
Functional clustering of the array data was performed by a
method based on overrepresentation of Gene Ontology (GO)
terms [21].
For the primary hepatocytes, expression levels were cal-
culated applying the multichip-modified gamma model for
oligonucleotide signal (multi-mgMOS) [22] and a remapped
chip description file [23].
All microarray datasets were deposited to gene expression
omnibus (GEO). The GEO series accession numbers are as
follows: study 1: GSE8290, study 2: GSE8291, study 3: GES
8292, study 4: GSE8295, primary hepatocytes: GSE8302.
2.5. RNA isolation and Q-PCR
Total RNA was extracted from tissues with TRIzol reagent
(Invitrogen, Breda, the Netherlands). 1 μg of total RNA was
reverse-transcribed with iScript (Bio-Rad, Veenendaal, the
Netherlands). cDNA was PCR-amplified with Platinum Taq
DNA polymerase (Invitrogen) on a Bio-Rad iCycler or MyIQ
PCR machine. Primers were designed to generate a PCR
amplification product of 100–200 bp and were taken from
Primerbank (http://pga.mgh.harvard.edu/primerbank).
Specificity of the amplification was verified by melt-curve
analysis and evaluation of eﬃciency of PCR amplification.
The sequence of primers used is available upon request. The
mRNA expression of all genes reported was normalized to
36B4 or cyclophilin gene expression.
2.6. In silico screening of putative PPREs using
a PPRE classifier
Genomic sequences for mouse genes spanning 20 kbp cen-
tered at the transcriptional start site (TSS) were extracted
from the Ensembl database (NBCI36) and screened for DR1-
type REs with predicted binding strength of at least 1%. The
binding strength prediction was based on a PPRE classifier
that uses a database of in vitro binding data for PPARs to
assign predicted binding strength according to a classifica-
tion scheme (Matilainen et al. submitted). The conservation
of the putative PPREs between mouse, human, dog, and rat
were evaluated using the Vertebrate Multiz Alignment and
Conservation track available from UCSC genome browser
(NCBI releases for human and mouse genomes, hg18 and
mm8, February 2006).
2.7. Histological examination of liver
5 μ sections were cut from frozen liver pieces. For oil red O
staining, sections were air dried for 30 minutes, followed by
fixation in formal calcium (4% formaldehyde, 1% CaCl2).
Oil red O stock solution was prepared by dissolving 0.5 g oil
red O in 500 mL isopropanol. An oil red O working solution
was prepared by mixing 30 mL oil red O stock with 20 mL
dH2O. Sections were immersed on working solution for 10
minutes followed by extensive washes in H2O. Haematoxylin
and eosin staining of frozen liver sections was carried out as
described (http://www.ihcworld.com/histology.htm).
3. RESULTS
3.1. Global analysis of PPARα-dependent
gene regulation
We analyzed the data from 4 independent microarray stud-
ies to obtain a comprehensive picture of PPARα-dependent
upregulation of gene expression in mouse liver. In the
first study, mRNA was compared between livers of 24-
hour fasted wild-type and PPARα-null mice. In the sec-
ond study, mRNA was compared between liver of wild-
type mice and PPARα-null mice fed the PPARα agonist
Wy14643 for 5 days. In these two studies, RNA was pooled
from 4-5 mice and hybridized to Aﬀymetrix MOE430A
GeneChip arrays. Since no biological replicates were ana-
lyzed, only a fold-change threshold criteria could be ap-
plied. Using a cutoﬀ of 1.5-fold, expression of a total of
1847 probesets was lower in 24-hour fasted PPARα-null mice
compared with 24-hour fasted wild-type mice (Figure 1(a))
(http://nutrigene.4t.com/microarray/ppar2007). Using the
same cutoﬀ, 2234 probesets were at least 1.5-fold lower
in the livers of PPARα-null mice fed Wy14643 com-
pared to wild-type mice fed Wy14643 (http://nutrigene.4t
.com/microarray/ppar2007). The number of probesets that
overlapped between the two groups was 569. A large propor-
tion of these genes, which are thus under control of PPARα
under pharmacological and physiological conditions, may
represent target genes of PPARα.
In the third study, mRNA was compared between liv-
ers of wild-type mice and PPARα-null mice treated with
Wy14643 for 6 hours, while in the fourth study mRNA was
compared between livers of wild-type mice and PPARα-null
mice fed Wy14643 for 5 days. Study 4 was carried out in-
dependently of study 2 in a diﬀerent set of mice. For these
two studies, biological replicates (4-5 mice per group) were
run using Aﬀymetrix mouse genome 430 2.0 GeneChip
array, enabling statistical analysis of the data which was
not possible for studies 1 and 2. Applying a false discov-
ery rate of 0.01 and a 1.5-fold cutoﬀ, 1679 probesets were
lower in the livers of PPARα-null mice compared to wild-
type mice 6 hours after treatment with Wy14643, and 2207
probesets after 5 days of feeding Wy14643 (Figure 1(b))
(http://nutrigene.4t.com/microarray/ppar2007). While the
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1278 569 1665
WT 24h fast versus
PPARα− /− 24h fast
WT Wy14643 5d versus
PPARα− /− Wy14643 5d
(a)
678 1001 1206
WT Wy14643 5d versus
PPARα− /− Wy14643 5d
WT Wy14643 6h versus
PPARα− /− Wy14643 6h
(b)
Figure 1: Microarray analysis of PPARα-dependent gene regulation
in mouse liver. (a) Venn diagram showing the number of diﬀer-
entially expressed probesets between livers of 24-hour fasted wild-
type and PPARα-null mice, and between wild-type and PPARα-null
mice treated with the PPARα agonist Wy14643 for 5 days. Pooled
RNA was hybridized to Aﬀymetrix MOE430A arrays. A fold-change
of >1.5 was used as cutoﬀ. (b) Venn diagram showing the num-
ber of diﬀerentially expressed probesets between livers of wild-type
and PPARα-null mice treated with the PPARα agonist Wy14643 for
6 hours, and between wild-type and PPARα-null mice treated with
the PPARα agonist Wy14643 for 5 days. RNA from individual mice
was hybridized to mouse 430 2.0 arrays. Probesets that satisfied the
criteria of fold-change >1.5 and FDR <0.01 were considered to be
significantly regulated.
majority of genes regulated by PPARα after 6 hours of
Wy14643 treatment were also, and generally more signifi-
cantly, regulated after 5 days of Wy14643 treatment (overlap
of 1001 probesets), many genes were specifically or more sig-
nificantly regulated after 6 hours, including the direct PPAR
target G0S2 and the EL gene, respectively. The complete set of
data from studies 2 and 4, which includes up- and downreg-
ulated genes, has been submitted to the Peroxisome Prolifer-
ators compendium assembled by Dr. J.C. Corton (US EPA,
Research Triangle Park, USA). They will be analyzed in con-
junction with numerous other microarray experiments in-
volving peroxisome proliferators to obtain the “peroxisome
proliferator transcriptome.” In addition, the datasets have
been submitted to GEO.
3.2. Pathway analysis of PPARα-dependent
gene regulation
Functional clustering analysis of the microarray data by Gene
Ontology classification indicated that numerous Gene On-
tology classes were overrepresented among the genes that
were >1.5-fold upregulated in 24-hour fasted wild-type com-
pared to 24-hour fasted PPARα-null mice. The same was
true for the comparison between wild-type and PPARα-
null mice treated with Wy14643 for 5 days. Among the
overrepresented Gene Ontology classes, we found many
classes that are known to be governed by PPARα, including
fatty acid beta-oxidation, acyl-CoA metabolism, leukotriene
metabolism, and peroxisome organization and biogene-
sis (http://nutrigene.4t.com/microarray/ppar2007). Interest-
ingly, we also noticed that numerous Gene Ontology classes
were specifically upregulated by PPARα under fasting con-
ditions or by Wy14643 feeding. The data suggest, for ex-
ample, that pyruvate metabolism and posttranslational pro-
tein targeting to membrane are specifically regulated in a
PPARα-dependent manner by Wy14643 but not by fasting.
Indeed, it is clear that some genes (e.g., Acot2 and Cd36)
are PPARα-dependently regulated by Wy14643 and much
less so by fasting, whereas others (e.g., Gpam, Hmgcs2)
are PPARα dependently regulated by fasting and much
less so by Wy14643. However, it is important to em-
phasize that the ErmineJ Gene Ontology classification, as
any functional clustering analysis, needs to be interpreted
carefully.
The Gene Ontology classification analysis of the com-
parison wild-type versus PPARα-null mice treated with
Wy14643 for 6 hours (study 3) was almost identical to the
analysis for mice treated with Wy14643 for 5 days (study 4),
suggesting that most of the gene expression changes elicited
by Wy14643 treatment are fast transcriptional responses in
correspondence with direct regulation of gene expression by
PPARα. One notable exception was the class representing the
acute phase response, which was regulated by 5-day but not
6-hour treatment with Wy14643.
3.3. Comprehensive list of PPARα-targets
involved in lipid metabolism
Using these lists of genes that are upregulated by PPARα in
mouse liver, we were able to create a comprehensive picture
of PPARα-regulated genes connected with lipid metabolism.
Genes in bold are PPARα dependently regulated by Wy14643
and during fasting, representing a conservative list of PPARα
targets (Figure 2). Genes in normal font are PPARα depen-
dently regulated in any of the four studies included. From
this picture, it is evident that rather than merely regulating
the rate limiting enzyme in fatty acid oxidation, PPARα ap-
pears to regulate virtually every single step in the peroxiso-
mal and mitochondrial fatty acid oxidation pathway. Fur-
thermore, many genes involved in fatty acid binding and
activation, lipid transport, and glycerol metabolism were
controlled by PPARα. What is remarkable is that PPARα
also governs the expression of numerous genes involved
in the synthesis of fats, which runs counter to the idea
that PPARα mainly regulates fat catabolism. Several genes
belonging to the lipogenic pathway have previously been
recognized as PPARα targets, including Mod1 and Scd1,
yet the extent of regulation by PPARα is unexpected [24].
Regulation of lipogenesis by PPARα was mainly observed
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Acot1
Acot7
Acot10
Acot12
Adipor2
Bdh
Etfb
Etfdh
G0s2
Lepr
Lpin2
Lrp4
Mlycd
Nr1h4 (FXR)
Scrab2
Pctp
Pdk4
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Aqp3
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Aqp9
Gpd1
Gpd2
Gyk
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Ces1
Ces3
Lipe
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Hadhb
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Slc25a20
Slc22a5
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Acsm3
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Lipid transport
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Abcb11
Abcg5
Abcg8
Npc1
Vldlr
Lrp4
Slc27a1
Slc27a2
Slc27a4
Cd36
Figure 2: Overview of PPARα-regulated genes involved in hepatic lipid metabolism. Genes in bold are PPARα-dependently regulated during
fasting and by Wy14643, representing a conservative list of PPARα targets. Genes in normal font are PPARα dependently regulated in any of
the four studies included. Functional classification is based on a self-made functional annotation system of genes involved in lipid metabolism
(http://nutrigene.4t.com/microarray/ppar2007).
after Wy14643 treatment, and to a much lesser extent after
fasting.
3.4. Novel putative targets of PPARα involved in
lipid metabolism
In addition to providing an overview of PPARα-dependent
gene regulation, we were interested in identifying novel
PPARα-regulated genes that are implicated in lipid
metabolism. To that end, we went through the array data
from studies 1 and 2 on the one hand, and studies 3 and 4 on
the other hand, and selected a number of genes to generate
a heat map showing their PPARα-dependent upregulation
by fasting and/or Wy14643 (Figure 3). To our knowledge,
none of the genes shown, all of which are involved in hepatic
lipid metabolism, has yet been reported to be regulated by
PPARα. This includes phosphatidylcholine transfer protein
(lipoprotein metabolism), glycerol-3-phosphate acyltrans-
ferase (triglyceride synthesis), very low-density lipoprotein
receptor, choline phosphotransferase (phosphatidylcholine
synthesis), and leptin receptor. Since all of these genes,
except Abcg5, Abcg8, and Lipe, were upregulated 6 hours
after Wy14643 treatment, they possibly represent novel
direct target genes of PPARα in liver, although PPREs have
yet to be identified in their respective gene promoters.
Eight genes (shown in bold, Figure 3) were selected for
more detailed investigation of PPARα-dependent gene reg-
ulation. Three of these genes are expected to be involved in
the breakdown of hepatic triglycerides towards fatty acids:
adipose triglyceride lipase (Pnpla2), hormone sensitive li-
pase (Lipe), and monoglyceride lipase (Mgll). Recent stud-
ies suggest that this threesome of genes is responsible for
adipose tissue lipolysis [25–27]. In addition, we selected en-
dothelial lipase (EL, Lipg), a recently identified member of
triglyceride lipase gene family that is a major determinant
of plasma HDL cholesterol [28–30], and electron transfer-
ring flavoprotein dehydrogenase (Etfdh) and electron trans-
ferring flavoprotein β polypeptide (Etfb), which are compo-
nents of the electron transport chain and accept electrons
from at least nine mitochondrial matrix flavoprotein dehy-
drogenases [31, 32]. Finally, we selected phosphatidylcholine
transfer protein (Pctp), which is involved in lipoprotein
metabolism, and thioredoxin interacting protein (Txnip),
which was recently identified as a major regulator of the
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Gene ID Gene name Description
1420656 at Abcg5 ATP-binding cassette, sub-family G (white), member 8
1419393 at Abcg8 ATP-binding cassette, sub-family G (white), member 5
1426146 a at Chpt1 Choline phosphotransferase 1
1455901 at Chpt1 Choline phosphotransferase 1
1435446 a at Chpt1 Choline phosphotransferase 1
1428181 at Etfb Electron transferring flavoprotein, beta polypeptide
1451084 at Etfdh Electron transferring flavoprotein, dehydrogenase
1419499 at Gpam Glycerol-3-phosphate acyltransferase, mitochondrial
1425834 a at Gpam Glycerol-3-phosphate acyltransferase, mitochondrial
1450391 a at Mgll Monoglyceride lipase
1453836 a at Mgll Monoglyceride lipase
1426785 s at Mgll Monoglyceride lipase
1418715 at Pank1 Pantothenate kinase 1
1420983 at Pctp Phosphatidylcholine transfer protein
1420984 at Pctp Phosphatidylcholine transfer protein
WT KO WT KO WT KO WT KO
Fed Fast - Wy 5d
(a)
Gene ID Gene name Description
1437864 at Adipor2 Adiponectin receptor 2
1419393 at Abcg5 ATP-binding cassette, sub-family G (white), member 5
1420656 at Abcg8 ATP-binding cassette, sub-family G (white), member 8
1455901 at Chpt1 Choline phosphotransferase 1
1435446 a at Chpt1 Choline phosphotransferase 1
1428181 at Etfb Electron transferring flavoprotein, beta polypeptide
1451084 at Etfdh Electron transferring flavoprotein,dehydrogenase
1425834 a at Gpam Glycerol-3-phosphate acyltransferase, mitochondrial
1456156 at Lepr Leptin receptor
1425644 at Lepr Leptin receptor
1425875 a at Lepr Leptin receptor
1422820 at Lipe Hormone sensitive lipase
1450188 s at Lipg Endothelial lipase
1421262 at Lipg Endothelial lipase
1452837 at Lpin2 Lipin 2
1452836 at Lpin2 Lipin 2
1450391 a at Mgll Monoglyceride lipase
1453836 a at Mgll Monoglyceride lipase
1426785 s at Mgll Monoglyceride lipase
1442560 at Mgll Monoglyceride lipase
1418715 at Pank1 Pantothenate kinase 1
1420983 at Pctp Phosphatidylcholine transfer protein
1420984 at Pctp Phosphatidylcholine transfer protein
1428143 a at Pnpla2 Adipose triglyceride lipase
1415996 at Txnip Thioredoxin interacting protein
1415997 at Txnip Thioredoxin interacting protein
1417900 a at Vldlr Very low density lipoprotein receptor
1434465 x at Vldlr Very low density lipoprotein receptor
1442169 at Vldlr Very low density lipoprotein receptor
WT KO WT KO WT KO WT KO
- Wy 6h - Wy 5d
0–0.5
0.5–0.75
0.75–1
1.01–1.2
1.2–1.4
1.4–1.6
1.6–1.8
1.8–2
2–2.2
2.2–2.5
2.5–3
3–3.5
3.5–4
4–4.5
4.5–5
5–6
6–7
7–8
8–9
9–10
10–15
15–20
20–30
30–50
50–100
100–
(b)
Figure 3: PPARα-dependent regulation in mouse liver of selected genes involved in lipid metabolism as shown by heat map. The (GCRMA
normalized) expression data were derived from 4 separate microarray studies. Expression levels in wild-type mice without treatment were
set at 1. (a) Expression data derived from studies 1 and 2. (b) Expression data derived from studies 3 and 4. Genes in bold were selected for
expression analysis by Q-PCR and in silico screening for putative PPREs.
hepatic response to fasting, similar to PPARα. The selec-
tion of these genes was based entirely on perceived novelty
and potential functional importance of the observed regu-
lation. Using real-time quantitative PCR (Q-PCR), we con-
firmed that the expression of all 8 genes in liver was in-
creased by Wy14643 feeding in a PPARα-dependent man-
ner (Figure 4(a)). In addition, we measured regulation of ex-
pression of this set of genes by PPARα during the course of
fasting (Figure 4(b)). Expression of all 8 genes went up dur-
ing fasting which, except for Pnpla2, was PPARα-dependent.
However, the pattern of expression was remarkably diﬀerent
between the various genes, suggesting for each gene a com-
plex and unique interplay between several fasting-dependent
transcription factors, including PPARα.
3.5. PPARα-dependent regulation in primary
hepatocytes
To examine whether the PPARα-dependent regulation of
the set of genes shown in Figure 3 was not an indirect
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Figure 4: PPARα governs expression of selected genes in mouse liver. (a) Regulation of expression of selected genes by Wy14643-feeding
(5 days) in liver of wild-type (+/+) and PPARα-null mice (−/−), as determined by Q-PCR. Error bars represent SEM. Diﬀerences were
evaluated statistically using two-way ANOVA. Significance (p-value) of eﬀect of genotype (G), treatment (T) and interaction (I) between
genotype and treatment is indicated in each figure. (b) Regulation of expression of selected genes by fasting in liver of wild-type () and
PPARα-null mice (), as determined by Q-PCR. Error bars represent SEM. Diﬀerences in expression between wild-type and PPARα-null
mice at each time point were evaluated by Student t test. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001.
consequence of metabolic perturbations elicited by the
experimental challenge, we studied the eﬀect of PPARα acti-
vation in primary mouse, rat, and human hepatocytes. Gene
expression was first analyzed by microarray (Figure 5(a)),
followed by targeted analysis of the selected 8 genes by Q-
PCR (Figure 5(b)). Expression levels were calculated by ap-
plying a multichip modified gamma model for oligonu-
cleotide signal (multi-mgMOS) [22] and a remapped chip
description file [23] to allow for parallel analysis of the same
gene within diﬀerent species. Expression of almost every gene
studied was highly upregulated by Wy14643 in mouse and
rat hepatocytes, compared to a more modest or no induction
in human hepatocytes. For reasons that are not completely
clear, in human hepatocytes, data from Q-PCR and microar-
ray did not always perfectly align. Overall, the data indi-
cate that the PPARα-dependent regulation observed in vivo
can be reproduced in primary hepatocytes. Furthermore, the
data suggest that expression of 6 genes is governed by PPARα
in human as well.
3.6. In silico screening of putative PPREs
To evaluate whether the selected eight genes represent pos-
sible direct PPAR target genes, the (mouse) genes were an-
alyzed for the presence of putative PPREs using an in silico
screening method (Figure 6). Ten kbp up- and downstream
of the TSS were examined. For each putative PPRE identified,
the predicted PPAR subtype specific binding strength was de-
termined. For each gene, at least one PPRE was identified
that was conserved among rat, dog, and human. The Etfdh
and Txnip genes were characterized by the presence of two
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Abcg5 ATP-binding cassette, subfamily G (white), member 8
Abcg8 ATP-binding cassette, subfamily G (white), member 5
Adipor2 Adiponectin receptor 2
Chpt1 Choline phosphotransferase 1
Etfb Electron transferring flavoprotein, beta polypeptide
Etfdh Electron transferring flavoprotein, dehydrogenase
Gpam Glycerol-3-phosphate acyltransferase, mitochondrial
Lepr Leptin receptor
Lipe Hormone sensitive lipase
Lipg Endothelial lipase
Lpin2 Lipin 2
Mgll Monoglyceride lipase
Pank1 Pantothenate kinase 1
Pctp Phosphatidylcholine transfer protein
Pnpla2 Adipose triglyceride lipase
Vldlr Very low density lipoprotein receptor
Txnip Thioredoxin interacting protein
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Figure 5: Regulation of selected genes involved in lipid metabolism in primary hepatocytes by Wy14643. (a) Microarray-based heat map
showing relative expression levels of genes calculated using a multichip modified gamma model for oligonucleotide signal (multi-mgMOS)
and a remapped chip description file. Expression levels in the absence of ligand were set at 1. (b) Relative induction of expression of selected
genes in primary hepatocytes by Wy14643, as determined by Q-PCR. The primary hepatocytes used for Q-PCR and microarray analysis
were from independent experiments. Genes were not included when expression was extremely low (Ct > 30). Error bars represent SD. The
eﬀect of Wy14643 on gene expression was evaluated by Student t test. ∗P < .05; ∗∗P < .01.
very strong putative PPREs that were conserved in human.
Up to six putative PPREs were identified in the Mgll gene,
only one of which was conserved in human. A similar pic-
ture was found for Pnpla2. The putative PPREs located in
the EL gene were weak and generally not conserved. Interest-
ingly, a strong putative PPRE was identified in the Pctp gene,
which however was not conserved in human. Conversely, the
human Pctp gene contained several putative PPREs that were
not conserved in mouse (data not shown).
3.7. PPARα activation prevents hepatic lipid storage
after fasting
Our data extend the role of PPARα in hepatic lipid
metabolism and suggest that PPARα may govern triglyceride
hydrolysis. To find out whether activation of the triglyceride
hydrolysis pathway by PPARα is associated with a decrease
in hepatic triglyceride stores, we compared wild-type and
PPARα-null mice fed an HFD for 20 weeks, followed by treat-
ment for one week with Wy14643. Numerous studies, includ-
ing ours [33], have shown that chronic HFD increases hep-
atic triglyceride stores. In wild-type mice fed the HFD, treat-
ment with Wy14643 markedly decreased hepatic lipids (Fig-
ures 7(a) and 7(b)), as shown by smaller lipid droplets, which
was paralleled by significant induction of expression of Pn-
pla2, Lipe, and Mgll (Figure 7(c)). These data suggest that
induction of the triglyceride hydrolysis pathway may con-
tribute to the overall reduction in liver triglycerides elicited
by PPARα activation.
4. DISCUSSION
The aim of our study was twofold: (1) to generate a com-
prehensive overview of PPARα-regulated genes relevant to
hepatic lipid metabolism, and (2) to identify possible novel
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Figure 6: In silico screening for putative PPREs for the selected 8 genes, 10 kbp up- and downstream of the transcriptional start site were
examined for the presence of putative PPREs. For each putative PPRE identified, the predicted PPAR subtype specific binding strength was
determined, as reflected by the height of the bar. The sequence conservation of the PPRE among various species is indicated.
target genes and target pathways of PPARα connected with
lipid metabolism.
It can be argued that to identify possible novel PPARα
targets, the proper comparison should have been between
wild-type and wild-type treated with Wy14643, as opposed
to wild-type treated with Wy14643 and PPARα-null treated
with Wy14643, in order to avoid inclusion of genes that
are diﬀerentially expressed between wild-type and PPARα-
null mice under basal conditions (and could represent genes
indirectly regulated by PPARα). The rationale behind our
decision was that we wanted to be open-minded about
the PPARα-dependent transcriptome and not exclude genes
that are solely regulated by PPARα under basal conditions.
For example, opting for the comparison wild-type versus
wild-type treated with Wy14643 would have led to the ex-
clusion of Etfdh, which according to our data represents
a prime candidate PPARα target gene in mouse and hu-
man. Furthermore, to enable comparison between the ef-
fects of fasting and Wy14643, it was essential to include
the PPARα dependency, since the majority of genes reg-
ulated by fasting are regulated in a PPARα-independent
manner.
Gene Ontology classification analysis showed that nu-
merous pathways and biological processes beyond lipid
metabolism were regulated by PPARα. We observed that the
expression of almost 1700 probesets was significantly in-
creased 6 hours after a single oral dose of Wy14643. Although
not all genes regulated may represent direct PPARα targets,
and even though the functional consequences of the ob-
served regulation still needs to be demonstrated, these data
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Figure 7: Induction of the triglyceride hydrolysis pathway by Wy14643 is paralleled by a decrease in hepatic lipid stores. Hematoxilin and
eosin staining (a) and oil red O staining (b) of representative liver sections of wild-type and PPARα-null mice treated or not with Wy14643
for 7 days (magnification 200X). All mice were given an HFD for 20 weeks prior to Wy14643 treatment. (c) Hepatic expression of Mgll, Lipe,
and Pnpla2 in the 4 experimental groups as determined by Q-PCR. Error bars represent SEM. Diﬀerences were evaluated statistically using
two-way ANOVA. Significance (p-value) of eﬀect of genotype (G), treatment (T), and interaction (I) between genotype and treatment is
indicated in each figure.
at least suggest a major role for PPARα in hepatic gene ex-
pression and overall liver homeostasis.
In agreement with the first aim, we created a compre-
hensive overview of hepatic PPARα-regulated genes con-
nected to lipid metabolism (Figure 2). A functional PPRE
has been found in the promoter of several of these genes,
classifying them as direct PPARα target genes, and many
more genes have been shown to be upregulated by PPARα
without a functional PPRE having been identified [24].
It can be presumed that the far majority of genes pre-
sented in Figure 2 (as well as the other genes that were
shown to be regulated by PPARα) are actually direct tar-
get genes of PPARα, but it is beyond the scope and capac-
ity of the present study to address this issue in more de-
tail. Our hope is that by combination of expression arrays
with global analysis of promoter occupancy by PPARα us-
ing chromatin immunoprecipitation and tiling or promoter
arrays (so-called ChIP-on Chip analysis), the complete pic-
ture of direct PPARα target genes will be available in the
future.
The second aim of our study was to identify possible
novel target genes of PPARα representing specific steps in
lipid metabolism unknown to be governed by PPARα. As
part of this eﬀort, we identified several genes for which a
link with PPARα has not yet been reported, including VLDL
receptor, leptin receptor, and choline phosphotransferase.
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We focused our energy on 8 genes for which regulation by
PPARα was deemed most novel and functionally interesting.
All 8 genes, except for Lipe, were significantly upregulated
6 hours after treatment with Wy14643.
Using an in silico method to screen for PPREs, for each
gene several putative PPREs could be located within 10 kbp
of the transcriptional start site. Within this region, at least
one PPRE was identified that was conserved among rat, dog,
and human. The presence of multiple strong putative PPREs
within the mouse Mgll gene is in correspondence with the
marked regulation of Mgll expression in mouse liver and iso-
lated hepatocytes. To a lesser extent, this is also true for the
Pnpla2 and Pctp genes. Furthermore, the predicted presence
of 2 strong, well-conserved putative PPREs in the Etfdh and
Txnip genes is in agreement with the highest fold-induction
of these genes by Wy14643 in primary human hepatocytes.
Although in silico screening may not be able to substitute
for analysis of direct promoter binding by ChIP, the pre-
dictive power of the method explored has been shown to
be remarkably robust (Matilainen et al. submitted). Our
results also substantiate the developing notion that PPAR-
dependent gene regulation is generally mediated by multiple
PPREs, rather than a single PPRE.
One remarkable outcome of the global analysis of gene
regulation by PPARα is that PPARα appears to play a major
role in governing lipogenesis. While several genes involved in
lipogenesis were already known as PPARα targets, including
Δ5 and Δ5 desaturase (Fads), stearoyl-CoA desaturase (Scd),
microsomal triglyceride transfer protein (Mttp), and malic
enzyme (Mod1) [24], the extent of regulation of lipogenesis
is somewhat surprising, especially since PPARα is generally
considered to stimulate fat catabolism rather than fat syn-
thesis. It can be speculated that upregulation of fatty acid de-
saturation and elongation enzymes by PPARα might serve to
stimulate production of PPARα ligands, and is part of a feed-
forward action of PPARα that also includes autoregulation of
gene expression.
Although the triglyceride hydrolysis pathway in liver still
has to be fully elucidated, it may very well be similar to
the pathway operating in adipose tissue [27]. Adipose tis-
sue triglycerides are likely hydrolyzed in a three-step process
catalyzed by adipose triglyceride lipase (Pnpla2), hormone
sensitive lipase (Lipe), and monoglyceride lipase (Mgll) [25–
27, 34]. Remarkably, deletion of the Pnpla2 gene in mice not
only results in more adipose mass but also causes a marked
increase in lipid storage in a variety of organs, including liver
and heart, suggesting that the triglyceride hydrolysis path-
way is conserved between various organs [27]. Disabling the
PPARα gene is known to increase hepatic triglyceride accu-
mulation, especially under conditions of fasting [33, 35, 36].
Conversely, treatment with PPARα agonists lowers hepatic
triglyceride levels in various models of hepatic steatosis [37–
40]. The antisteatotic eﬀect of PPARα has generally been as-
cribed to stimulation of fatty acid oxidation, which, by de-
creasing intracellular fatty acid levels, will act as a drain on
intracellular triglyceride stores. However, our data suggest
that PPARα may directly govern the triglyceride hydrolysis
pathway in liver via upregulation of lipases Pnpla2, Lipe,
Mgll, and possibly Ces1 and Ces3 (Figure 2). Although it is
impossible to provide definite experimental proof that in-
duction of the triglyceride hydrolysis pathway by PPARα, or
induction of fatty acid oxidation for that matter, is neces-
sary and suﬃcient for its hepatic triglyceride-lowering eﬀect,
it likely contributes to the overall reduction in liver triglyc-
erides elicited by PPARα agonists.
Our data suggest that expression of EL is under control
of PPARα. EL, synthesized in endothelial cells, plays an im-
portant role in governing plasma lipoprotein concentrations
and is a major determinant of plasma HDL cholesterol and
apoAI concentrations. Indeed, overexpression of EL in the
liver results in a significant decrease in HDL cholesterol and
apoAI [28–30]. EL has been shown to have some triglyceride
lipase but mainly phospolipase activity [41]. Although in sil-
ico screening failed to detect a strong PPREs in this gene,
in our study EL expression was highly increased by 6 hours
Wy14643 treatment and by fasting in a PPARα-dependent
manner, suggesting that EL may be a direct PPARα target
gene. As EL expression was minimal in primary hepato-
cytes, EL transcripts likely originated from liver epithelial
cells rather than liver parenchymal cells. Although further
work is necessary, we suspect that EL may be a direct PPARα
target in endothelial cells. Considering that, in contrast to
EL, PPARα agonists raise plasma HDL, the functional im-
portance of regulation of EL by PPARα needs to be further
validated.
Another novel PPARα-regulated gene of relevance to
lipoprotein metabolism is Pctp. Pctp is a steroidogenic acute
regulatory-related transfer domain protein that binds phos-
phatidylcholines with high specificity. Studies with Pctp-null
mice suggest that it may modulate HDL particle size and
rates of hepatic clearance [42]. According to our data, ex-
pression of Pctp increases during fasting, which is abolished
in PPARα-null mice. Wy14643 markedly upregulated Pctp
mRNA in mouse liver as well as in mouse, rat, and human
hepatocytes, suggesting it may represent a novel PPARα tar-
get gene.
Etfdh and Etfb are essential components of the oxidative
phosphorylation pathway. They are responsible for the elec-
tron transfer from at least 9 mitochondrial flavin-containing
dehydrogenases to the main respiratory chain [31, 32]. Ac-
cording to our data, expression of Etfdh and Etfb is governed
by PPARα, suggesting that besides the β-oxidation pathway,
PPARα also regulates components of the respiratory chain
involved in the transfer of electrons from fatty acids and
other molecules.
The last gene that we studied in more detail was Txnip,
which is also known as Hyplip1. A spontaneous mutation
within the Txnip gene gives rise to a complex phenotype
that resembles familial-combined hyperlipidemia, including
hypercholesterolemia and hypertriglyceridemia [43]. Recent
studies suggest that Txnip plays an important metabolic role
in the fasting-feeding transition by altering the redox status
of the cell, which results in stimulation of the tricarboxylic
acid cycle at the expense of ketone body or fatty acid synthesis
[44]. Indeed, Txnip-deficient mice show elevated plasma ke-
tones, elevated free fatty acids, hypercholesterolemia, and hy-
pertriglyceridemia, yet decreased glucose levels [43, 45]. The
phenotype is very similar to that of PPARα-null mice with
12 PPAR Research
the exception of the elevated plasma ketones. Since hepatic
expression of Txnip is decreased in PPARα-null mice, it can
be hypothesized that part of the eﬀect of PPARα deletion on
lipid and glucose metabolism is mediated by downregulation
of Txnip in liver, which subsequently might aﬀect redox sta-
tus. It is unclear to what extent Txnip expression is aﬀected
by PPARα deletion in tissues other than liver.
In conclusion, our data indicate that the role of PPARα in
hepatic lipid metabolism is much more extensive than pre-
viously envisioned. By generating a schematic overview of
PPARα-dependent gene regulation in mouse liver, and, for
a selected set of genes, by providing evidence for direct reg-
ulation by PPARα in rodents and human, we have extended
the role of PPARα in the control of hepatic lipid metabolism.
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